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Plerixafor allows for rapid mobilization of hematopoietic
stem cells (HSCs) by disrupting the interaction of HSC re-
ceptor CXCR4 and bone marrow stromal cytokine SDF-1
alpha. When combined with granulocyte colony stimulating
factor (G-CSF) with or without chemotherapy, rates of suc-
cessful mobilization are increased in patients who have
previously failed to mobilize or have traits predictive of
failure. Current package labeling for plerixafor states that
leukapharesis (LP) should begin 10-11 hours post adminis-
tration, the time at which peak peripheral blood (PB) CD34+
cell counts have been observed. Phase I data in healthy vol-
unteers shows that peak PB CD34+ cell count is dose
dependent and that counts increase in a linear fashion be-
tween hours 1,3,6 and 9. Studies in HLA-matched sibling
donors have shown that minimum required yield for trans-
plant can be reached when LP begins 4 hours after plerixafor
injection. In our institution, due to time constraints, we
follow a model consistent with these previous studies and
begin LP 4-6 hours after plerixafor injection. In order to
assess efﬁcacy of this timing in patients undergoing autolo-
gous stem cell transplant (autoSCT), we completed a retro-
spective chart review of 43 patients; 25 with lymphoma and
18 with multiple myeloma (MM). The median percent
change in PB CD34+ cell count, prior to 1stLP, was 19.9% in
lymphoma and 13.45% in MM. 95% of patients reached the
minimumyield required for autoSCT in 4 days. One patient
with MM and one patient with lymphoma failed to collect
adequate levels of HSCs. The median total CD34+ yield was
4.33x106 and 6.73x106 in the lymphoma and MM groups
respectively. All but ﬁve patients proceeded to autoSCT.
Among the 38 patients that remained eligible for autoSCT,
themedian number of days for ANC and platelet engraftment
was 11 and 22 respectively. These results are comparable to
historical data, thus showing that high risk patients can
collect an adequate number of stem cells, in an expected
period of time, with good engraftment results using an
alternative plerixafor mobilization schedule.135
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Background: CD34+ cell-doses given during autologous
stem cell transplantation (ASCT) for multiple myeloma (MM)
patients (pts) can vary between pts depending on ability to
mobilize CD34+ cells and amount of CD34+ cells/kg collected
during the apheresis procedure. Published retrospective
studies suggest that absolute lymphocyte count (ALC) re-
covery may be a predictor of overall survival (OS), progres-
sion free survival (PFS), and infectious complications in ASCT.
It is unclear whether there is an optimal CD34+ cell-dose that
correlates with a shorter time to ALC recovery, possiblydecreasing infectious complications, and potentially
increasing time to relapse.
Methods: A retrospective analysis of ALC recovery was per-
formed on 12 consecutive MM pts who had undergone ASCT
from 1/2012 to 1/2013 at the University of Virginia to
determine if a relationship existed between CD34+ cell-dose
given during ASCT and ALC recovery. For each pt, number/
type of infection and ALCs were collected for the ﬁrst 100
days post-ASCT. OS and PFS were also assessed for each pt.
Cox proportional hazard models were used to estimate the
association of CD34+ cell-dose infused with time to ALC re-
covery after ASCT. ALC recovery was deﬁned as the ﬁrst day
of three consecutive measurements for three different cutoff
values: ALC  800, ALC  1000, and ALC  1500. No
competing risks occurred; therefore, the log rank test sta-
tistic was used to assess the signiﬁcance of the association.
Results: Median age was 60 years (range from 45-71 years),
75% were male, 67% had IgG MM, and 92% had kappa light
chain restriction. Fifty-eight percent had ISS Stage I MM and
33% had ISS Stage III disease. The analysis revealed that a
higher CD34+ cell-dose given during ASCT showed a trend
toward faster ALC recovery, when deﬁned as ALC  800
(p¼.043) and ALC  1000 (p¼.052). No difference was seen
for ALC  1500. Median times to achieving ALC  800 and
ALC  1000 were 43 and 59 days, respectively for pts given
CD34+ cell-dose < 4x106 cells/kg; and were 18 and 19 days
for pts given CD34+ cell-dose > 4x106 cells/kg. All ﬁve pts
transplanted with a CD34+ cell-dose < 4x106 cells/kg
developed at least one bacterial infection. Only one of the
seven pts transplantedwith CD34+ cell-dose> 4x106 cells/kg
developed bacterial complications. Eighty-two percent of
bacterial infections (n¼11) occurred in pts given CD34+ cell-
dose < 4x106cells/kg. Median time of follow-up was 12
months (range from 9 to 20 months). Two pts have relapsed,
at 10 and 13months, post-ASCTand no deaths have occurred.
Conclusion: These preliminary results suggest that CD34+
cell-dose > 4x106 cells/kg given during ASCT for MMmay be
associated with shorter ALC recovery and lower rates of in-
fections. However, larger prospective trials with longer
follow-up are necessary to further deﬁne optimal CD34+ cell-
dose infusion for ASCT in MM pts in order to improve ALC
recovery.136
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Background: The role of radiological surveillance with
Positron Emission Tomography (PET) or Computed Tomog-
raphy (CT) after completion of chemotherapy in patients
with lymphoma is controversial. Prior studies have shown
conﬂicting results in regards to the beneﬁt of screening for
patients with lymphoma using CT or PET versus clinical
detection of relapse. What is not known is whether
Table 1
Overall survival rate (OS) and thalassemia-free survival rate (TFS) of BMT
and PBSCT stratiﬁed by disease classes:
BMT PBSCT
OS 1 y 2 y 5 y p-value OS 1 y 2 y 5 y p-value
I 92.3% 92.3% 90.1% .148 I 81.7% 80.7% 78.0% .011
II 79.7% 79.7% 77.6% II 87.9% 85.2% 79.5%
III 79.7% 78.3% 76.3% III 75.1% 69.5% 64.0%
TFS 1 y 2 y 5 y p-value TFS 1 y 2 y 5 y p-value
I 80.8% 80.8% 78.8% .167 I 78.9% 77.9% 75.2% <.001
II 68.4% 67.0% 65.4% II 85.5% 81.9% 76.1%
III 67.7% 64.7% 60.6% III 66.0% 59.7% 55.2%
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advantage over relapse diagnosed by clinical means in pa-
tients with relapsed lymphoma undergoing subsequent
auto-SCT.
Methods: In an attempt to answer the above question, we
grouped all the patients with relapsed lymphoma (Hodgkin
and non-Hodgkin’s lymphoma) who were referred to our
center for auto-SCT between January 1, 2007 till December
31, 2012 in Cohort A (Relapse diagnosed by radiological
surveillance) and Cohort B (Relapse diagnosed by clinical
means based on new symptoms and examination ﬁndings).
All patients had biopsy proof of relapse prior to salvage
chemotherapy.
The primary objectives were post-transplant relapse and
disease-free survival. Kaplan-Meier and the Log-rank test
were used for analysis.
Results: A total of 133 patients were included in the analysis,
with 74 patients in the radiographic screening Cohort A and
59 patients in the symptomatic/clinical relapse Cohort B.
Clinically important patient characteristics were similar be-
tween the two cohorts. The clinical stage at relapse leading to
transplant, salvage chemotherapy regimens and number of
cycles used prior to transplant, response to salvage chemo-
therapy, time to transplant, and 100-day post-transplant
outcomes were not statistically different between the two
groups. Nine patients died in cohort A, 5 of whom were due
to disease relapse. Thirteen patients died in cohort B, 7 due to
disease relapse. The 3-year relapse-free survival was 54% in
Cohort A and 46% in Cohort B. There was no statistically
signiﬁcant difference in the relapse-free-survival between
the two cohorts (p¼.26). The median duration of follow-up
for Cohort A was 23.7 months (range 0.61-73.11) and for
Cohort B was 13.57 months (range 0.36-57.0). When the
same analysis was conducted in patients with non-Hodgkin’s
lymphoma (excluding data for Hodgkin’s disease), the results
were similar. Median duration of survival was not reached, so
no attempt was made to comment on overall survival in this
small cohort with few events to analyze.
Conclusions: In this single center study, we showed that
routine radiological surveillance after completion of
chemotherapy did not improve relapse-free-survival in pa-
tients with lymphoma undergoing subsequent auto-SCT. We
plan to start a prospective study exploring the role of routine
radiological surveillance after auto-SCT in patients with
lymphoma to answer another important question.137
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Introduction: HSCT is the treatment of choice for patients
with thalassemia. Here, we report our hematopoietic stem
cell transplantation experience in the treatment of thalas-
semia major patients, using PBSCT versus BMT.Patients and Methods: From 1992 to 2013, 574 patients
underwent HSCT in our centre. 221 patients received HSCT
from BMT and 353 patients from PBSCT. The median age in
the BMT group was 7years (2-26years) and in the PBSCT
group was 8 years (2-29 years) (P-Value¼.001). In BMTgroup
89(40.3%) patients were class III whereas in PBSCT group
were 121(34.3%) (P-Value¼.196).
Results: Acute graft versus host disease (GvHD) occurred in
141(63.80%) and 253(71.70%) of patients in the BMT and
PBSCT, respectively (P-Value¼.048). Chronic GvHD was
19.30% in the BMTand 32.70% in the PBSCT (P-Value¼.001) in
survivors after 100 days. With a median follow-up of
50months, the 5-year thalassemia-free survival rate (TFS) of
BMT and PBSCT were 76.3% and 67.5%, respectively (P-Val-
ue¼.294). The 5-year overall survival rate (OS) in BMT and
PBSCT were 80.1% and 73.8%, respectively (P-Value¼.119).
The rejection was 16.3% and 6.5% in BMT and PBSCT,
respectively. The most common causes of death were GvHD
and infections in both groups. TFS and OS results stratiﬁed by
disease class showed better survival rates in lower classes
(Table1).
Conclusion: The PBSCT was an easier procedure for donors
with lower cost compared with BMT. Acute GvHD was
slightly more in PBSCT but chronic GvHDwas more frequent.
Chronic GvHDwas alleviated over time and also it seems that
the rejection is lower in PBSCT. These results show that HSCT
should be considered for lower class of thalassemia and
PBSCT is an acceptable alternative.138
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Racial and ethnic disparities have been reported in the uti-
lization of autologous and allogeneic BMT and in the avail-
ability of allogeneic donors for minority populations. In
addition, adults in general, and minorities in particular, have
low rates of participation in research studies. Several factors
may lead to under-utilization of BMT and lack of clinical trial
participation, such as differential access to care, co-morbid-
ities, tobacco use, obesity and mistrust of the medical system
due to previous unethical practices with minorities in
research studies. We investigated the low rates of minorities
1) referred for BMT consultation, 2) undergoing BMT as
therapy, and 3) participating in biospecimen and survey
research at a single U.S. center by performing a population
based analysis using New York State (NYS) Department of
